Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
A new survey shows employer coverage of GLP-1 drugs for obesity has stalled, with many companies seeking workarounds instead of expanding benefits.
Employer coverage of GLP-1 medications for weight loss has flatlined, with a new survey revealing that roughly 36% of companies now cover the blockbuster drugs for both diabetes and obesity treatment — unchanged from 2025 and only marginally above the 34% recorded in 2024. The stagnation signals that despite surging demand for drugs like Ozempic and Wegovy, most employers are not moving aggressively to expand access through their health plans.
Rather than broadening coverage, many employers are actively seeking alternative strategies to manage costs tied to the expensive drug class. GLP-1 medications can run thousands of dollars per patient annually, creating significant budgetary pressure on corporate health plans already strained by rising medical inflation. The search for workarounds reflects a broader tension between employee demand for weight-loss treatments and the financial realities facing benefits administrators.
Read more Meta Breaks Ground on First Major Canadian Data Center →
The near-flat coverage numbers over two consecutive years suggest the initial wave of employer adoption may have crested, at least for now. Companies that chose not to cover GLP-1s for weight loss early on appear to be holding that position, while those that did adopt coverage are unlikely to reverse course given the workforce retention implications tied to competitive benefits packages.
Analysts watching the employer benefits space note that the stalemate could shift if drug manufacturers lower list prices or if biosimilar competition eventually enters the market, reducing the per-member cost burden. Until then, the gap between employee expectations and employer willingness to pay for obesity-focused GLP-1 coverage appears set to persist. Continue reading at US Top News and Analysis.
